[18F]AlF与68Ga标记双靶向异二聚体FAPI-RGD在恶性肿瘤中的比较:临床前评价与初步临床PET/CT显像
本研究制备了靶向成纤维细胞激活蛋白(FAP)和整合素αvβ3的双靶向异二聚体示踪剂[18F]AlF-NOTA-FAPI-RGD([18F]AlF-LNC1007),并在U87MG细胞系及其异种移植模型中与[68Ga]Ga-LNC1007进行临床前比较,同时在6例恶性肿瘤患者中评估其安全性和剂量学。两种示踪剂药代动力学特征相当,肿瘤摄取高且滞留时间长;[18F]AlF-LNC1007全身有效剂量为9.94E-03 mSv/MBq,初步临床PET/CT显像质量良好。
要点
- [18F]AlF-LNC1007与[68Ga]Ga-LNC1007在临床前模型中表现出相当的药代动力学特征和靶/非靶比值。
- 6例恶性肿瘤患者接受[18F]AlF-LNC1007 PET/CT,全身有效剂量为9.94E-03 mSv/MBq。
- 肿瘤滞留时间长达注射后3小时,且肿瘤/背景比值随时间增加。
核心结论
- 成功制备了[18F]AlF-LNC1007双靶向PET探针,其性能与[68Ga]Ga-LNC1007相当。
- 该探针具有延长的肿瘤滞留和肿瘤特异性,在临床前和临床转化研究中产生了良好的显像质量,作者认为其是检测表达FAP和/或整合素αvβ3的肿瘤的有前景的无创示踪剂,具有临床实施前景。
研究设计与样本
- 临床前研究:在U87MG细胞系及其异种移植模型上比较[18F]AlF-LNC1007与[68Ga]Ga-LNC1007的细胞摄取和体内分布。
- 临床研究:在6例恶性肿瘤患者中评估[18F]AlF-LNC1007 PET/CT的安全性和剂量学,其中2例进行了头对头[18F]FDG PET/CT扫描。
主要发现
- 两种示踪剂在PBS和胎牛血清(FBS)中稳定性良好,放射标记产率高。
- 体内microPET显像显示两种示踪剂药代动力学特征相当,肿瘤摄取高且滞留时间长。
- 体内分布数据显示[18F]AlF-LNC1007的靶/非靶比值与[68Ga]Ga-LNC1007相似。
- [18F]AlF-LNC1007 PET/CT的全身有效剂量为9.94E-03 mSv/MBq。
- 生物分布曲线显示正常器官摄取良好,肿瘤摄取高且滞留时间长达注射后3小时,肿瘤/背景比值随时间增加。
关键数值与推荐
- [18F]AlF-LNC1007全身有效剂量为9.94E-03 mSv/MBq。
- 肿瘤滞留时间长达注射后3小时,肿瘤/背景比值随时间增加。
临床怎么用
- 原文未据此给出临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
UNLABELLED: Due to the heterogeneity of tumors, strategies to improve the effectiveness of dual-targeting tracers in tumor diagnostics have been intensively practiced. In this study, the radiolabeled [18F]AlF-NOTA-FAPI-RGD (denoted as [18F]AlF-LNC1007), a dual-targeting heterodimer tracer targeting both fibroblast activation protein (FAP) and integrin αvβ3 to enhance specific tumor uptake and retention, was synthesized and evaluated. The tracer was compared with [68Ga]Ga-LNC1007 in preclinical and clinical settings. METHODS: The preparation of [18F]AlF- and 68Ga-labeled FAPI-RGD was carried out with an optimized protocol. The stability was tested in PBS and fetal bovine serum (FBS). Cellular uptake and in vivo distribution of the two products were compared and carried out on the U87MG cell line and its xenograft model. The safety and dosimetry of [18F]AlF-LNC1007 PET/CT scan were evaluated in six patients with malignant tumors. RESULTS: Two radiolabeling protocols of [18F]AlF-/[68Ga]Ga-LNC1007 were developed and optimized to give a high yield of tracers with good stability. In vivo microPET images showed that the two tracers exhibited comparable pharmacokinetic characteristics, with high tumor uptake and prolonged tumor retention. In vivo distribution data showed that the target-to-non-target ratios of [18F]AlF-LNC1007 were similar to[68Ga]Ga-LNC1007. A total of six patients underwent [18F]AlF-LNC1007 PET/CT evaluation while two had head-to-head [18F]FDG PET/CT scans. The total body effective dose was 9.94E-03 mSv/MBq. The biodistribution curve showed optimal normal organ uptake with high tumor uptake and long retention of up to 3h p.i., and notably, the tumor-to-background ratio increased over time. CONCLUSION: We successfully prepared an [18F]AlF-LNC1007 dual-targeting PET probe with comparable performances as [68Ga]Ga-LNC1007. With prolonged tumor retention and tumor specificity, it produced good imaging quality in preclinical and clinical translational studies, indicating that [18F]AlF-LNC1007 is a promising non-invasive tracer for detecting tumors expressing FAP and/or integrin avβ3, with the prospect of clinical implementation.
引用
- Liu N, Wan Q, Wu X, et al. A comparison of [18F]AlF- and 68Ga-labeled dual targeting heterodimer FAPI-RGD in malignant tumor: preclinical evaluation and pilot clinical PET/CT imaging. Eur J Nucl Med Mol Imaging. 2024. PMID: 38246909. doi:10.1007/s00259-023-06587-5
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。